420 with CNW — Can Tenants Smoke Marijuana Within Rental Properties?

Twenty-one states now allow their residents to purchase, possess and consume recreational cannabis while 37 states have medical marijuana programs. Millions of people now have access to cannabis for either medical or recreational purposes, but both state and federal laws prevent public consumption of marijuana. As a result, most people consume cannabis at home.

States laws that decriminalized cannabis allowed people to possess, grow and smoke cannabis in private residences including rental properties. While this isn’t a big issue for products such as edibles, extracts and creams, smoking at home can be a contentious issue, especially for people who are renting their homes.

As more states have legalized private cannabis consumption, there has been an increase in complaints from neighbors and landlords about tenants smoking at home.

In January, a 76-year-old Washington, DC, resident sued the District of Columbia over the smell of cannabis regularly wafting into her home. However, she may not have any legal recourse as private cannabis smoking is allowed by Washington, DC, state law.

If a landlord discovers that a tenant is smoking cannabis, they cannot terminate their lease based on that fact alone if they did not explicitly ban smoking in the rental agreement. On the other hand, a tenant cannot smoke cannabis in their home if their rental agreement stated that smoking on the property wasn’t allowed. If such a tenant smokes cannabis indoors, their actions will constitute a breach of contract, and their landlord will have a solid legal basis to terminate the lease.

The landlord will first be required to provide the tenant with three consecutive written warnings instructing them to stop smoking. After the third warning is issued, the landlord can cancel the lease agreement and give their tenant notice to vacate.

If you smoke cannabis or plan to smoke in the future, make sure your landlord has not included provisions banning indoor smoking in the rent agreement.

Additionally, note that even if your home is deemed a smoking unit, you will be required to prevent your smoking from damaging the home. You may also have to pay for any damage to the property caused by smoking to restore it to its condition before you moved in. This damage includes discolored walls or carpets that smell of marijuana and will need repainting and carpet cleaning or replacing to mitigate.

To keep yourself protected, make sure you review your rent agreement carefully and opt for a unit that allows smoking. Furthermore, you will want to take steps and prevent your smoking from damaging the home to reduce your costs when your lease elapses.

For patients who look to marijuana for therapeutic purposes, a less contentious option could soon be available if entities such as India Globalization Capital Inc. (NYSE American: IGC) succeed in getting FDA approval and commercializing formulations targeting different health complications.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Study Finds Link Between Medical Cannabis Legalization, Reductions in Payments for Opioids

Dozens of states now allow their residents to use medical cannabis to alleviate more than 20 qualifying medical conditions. Although the research on cannabis is still relatively new, there is strong proof that cannabis-based treatments can alleviate the symptoms of a wide variety of medical conditions.

As a result, millions of Americans across the country now use medical cannabis to treat conditions such as chronic pain, insomnia, anxiety disorders and others. One of the most common uses of medical cannabis is to treat chronic pain, a condition that is estimated to affect an estimated 50.2 million adults in America.

With more and more people turning to cannabis to alleviate their medical conditions, researchers have noted that they are using fewer pharmaceutical opioids. In a new study from the University of Southern California, Purdue University and the University of Florida, researchers said that there has been a significant reduction in direct payments from opioid producers to physicians.

The researchers found that clinicians in states with medical marijuana programs are prescribing fewer opioids to their patients. They used a new “penalized synthetic control model” to review transaction data on direct payments to physicians from opioid manufacturers between 2014 to 2017. Their aim was to determine if there was a causal relationship between the launch of medical marijuana markets and reductions in payments for opioids.

They found evidence indicating that the presence of medical marijuana as an alternative treatment contributed to the reduced payments to opioid manufacturers. Female clinicians and areas with less affluent and higher concentrations of white, working-age populations saw a higher substitution effect. Opioids have been integral in the treatment of pain for decades, and tens of millions of people across the world have used them to manage pain disorders.

Direct payments to physicians help manufacturers to spread their reach and access more customers for their products. However, opioids aren’t always effective, and they have a significant risk of causing side effects such as nausea, constipation and respiratory depression. They can also lead to physical dependence and contribute to the development of opioid use disorder, which affects more than 15 million people globally and causes more than 120,000 deaths across the world annually.

As a result, plenty of chronic pain patients have adopted cannabis as an alternative treatment in place of conventional pharmaceuticals. This study adds to a growing body of literature indicating that more patients are choosing medical cannabis over opioids to manage chronic pain.

Given that chronic pain is a major affliction in the United States and around the world, enterprises such as India Globalization Capital Inc. (NYSE American: IGC) are focused on coming up with cannabis-based therapeutic formulations, which can be approved by the FDA for use against this clinical indication that often compromises the quality of life of the people diagnosed with it.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — New York Medical Marijuana Companies Sue State Regulators Over Licensing Implementation

A coalition of medical marijuana companies in New York is suing state cannabis regulators over licensing implementation provisions that prioritized social equity applicants. Most states with legal cannabis markets have included social equity and justice provisions that seek to compensate members of communities that were disproportionately affected by cannabis prohibition. In cases such as New York, this involved giving people with certain prior cannabis criminal records or their relatives priority access to the license application pool.

The Coalition for Access to Regulated & Safe Cannabis argued in its lawsuit that cannabis regulators overstepped their legal authority by limiting the initial applications to a limited amount of applicants instead of allowing the entire market to apply. The New York Office of Cannabis Management and the Cannabis Control Board as well as several top officials were named in the suit.

New York was a late entrant into the cannabis market and is still working to get its cannabis industry off the ground. The state has currently awarded 66 dispensaries with retail licenses, and the state’s fifth store opened its doors to customers this week.

According to a coalition spokesperson, companies represented by the trade association, including Acreage Holdings, Green Thumb Industries and Curaleaf, have been unable to enter the recreational cannabis market because of the state’s limited licensing program. A memo filed with the suit states that the regulators “overstepped their rule-making authority” and held back the licensing of hundreds of retail cannabis outlets needed to fulfill customer demand for cannabis and compete with the massive black market for cannabis.

The lawsuit claims that state regulators are putting New Yorkers’ health at risk by limiting the application pool. As with California, New York is also home to a large illicit cannabis market that has made it difficult for the legal market to thrive.

New York cannabis regulators took more than a year after recreational cannabis was legalized to begin awarding retail licenses. In the meantime, significant numbers of illicit sellers sprang up across the state to satisfy cannabis demand that simply couldn’t be met by the legal market.

As the regulated market begins to grow, it will certainly struggle to compete with an illicit market that has had more time to become entrenched and that can sell products at significantly lower price points because black market sellers often skimp on testing and safety requirements to lower their costs.

An Office of Cannabis Management spokesperson did not comment on the lawsuit when asked.

In other news, more enterprises such as India Globalization Capital Inc. (NYSE American: IGC) are focusing on developing pharmaceutical-grade medicines from a number of marijuana constituents such as THC in order to combat the rising cases of chronic pain and other clinical indications.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Mississippi Farmers Switch from Hemp to Growing Marijuana

Mississippi approved the use of medical cannabis last year after a lengthy legislative debate, though local governments were given the option to reject the initiative. Lincoln County was one of the counties that initially declined to participate in the program.

However, the decision prompted Timothy Gibson and Jason McDonald to take the lead in pushing for the legalization of medical cannabis in the county. The two succeeded in getting the issue on the ballot in August last year when county voters overturned the decision made by local officials.

After the vote, they got to work on starting their own medical cannabis cultivation facility — SADUJA — located in East Lincoln. In December 2022, the facility received a license to cultivate medical cannabis, making it the first in Lincoln County. “We have been cultivating hemp since its legalization in Mississippi,” McDonald said. “We provided hemp to regional stores in the state. People may not have been aware that cannabis was grown here legally prior to the legalization of medical marijuana. It was present and flourishing on the farm.

“I think people are typically afraid of new things,” McDonald continued. “It is essentially the same as what we’ve been doing, but on a larger scale, and we switched from using hemp to using medical cannabis. The plant is the same.”

According to McDonald, the local community has turned its attention to the medical cannabis industry. People should be aware that applying to work at a cannabis cultivation facility is a difficult process. For employment at the tea farm, according to McDonald, he can hire anyone over the age of 16, but for the medical marijuana farm, applicants must be at least 21 years old, citizens without a history of felony convictions, and able to pass a background check.

The medical marijuana bill was a major point of contention within the state’s legislature and between legislators and Governor Tate Reeves, who was persistent in imposing strict restrictions on any measure that emerged. Reeves was particularly worried about how much cannabis a patient could legally obtain. The governor preferred a daily limit of 2.7 grams; however, the bill presented to him and passed by a veto-proof majority, permits patients to purchase up to 3.5 grams up to six times a week.

Following his signing of the bill into law, Reeves stated that while the bill was not the one he would have drafted, legislators who made the final version made major improvements to get the state closer to achieving its ultimate goal.

Worries such as those faced by Reeves could soon be partially addressed if organizations such as India Globalization Capital Inc. (NYSE American: IGC) succeed in bringing to market various formulations targeting the different conditions for which patients are enrolling for medical marijuana in different jurisdictions around the country.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Kentucky Senate Approves Medical Cannabis Legalization Bill

The Kentucky Senate recently passed medical cannabis legislation, just in time for the bill to advance to the House of Representatives. The move comes two days after the bill, SB 47, was approved by the Senate Licensing and Occupations Committee.

Previously, a bill to legalize medical marijuana was passed by the House last year and in a previous session, but the Senate did not take any action on those bills. Thus, proponents began working on the Senate side this session to improve the bill’s chances of passage.

Some provisions of the measure include:

Patients with severe pain, cancer, epilepsy, muscle spasms, multiple sclerosis, PTSD, chronic nausea or any other illness the state’s center for marijuana deem appropriate may be eligible to use cannabis as long as they have a medical practitioner’s prescription.
While smoking is prohibited, users can still access raw marijuana for vaporization.
Patients are allowed to keep up to 30 days of cannabis in their homes and up to 10 days on them at any given time.
Products made from marijuana flowers would have a THC cap of 35%, while concentrates would have a 70% cap.
The establishment of a nine-person Board of Advisors and Physicians made up of two advanced nurse practitioners and seven doctors.

One of the reform’s main obstacles has been Damon Thayer, Senate Majority Leader, who has vehemently opposed broad medical marijuana policy reform on the grounds that it would hasten the legalization of recreational cannabis. However, more recently, he declared that if the bill received enough support to pass, he would not obstruct it. This week, he voted in favor of the legislation in the senate committee, citing how well targeted it was. He also supported the bill during Thursday’s Senate debate.

Activists have constantly put pressure on legislators to pass reform this session, with organizations such as Kentucky NORML and Moms for Medical Marijuana (KMMC) making it clear that the issue has been in limbo for far too long.

In January, Kentucky Governor Andy Beshear (D) urged lawmakers to legalize medical marijuana, saying that doing so is a crucial reform that will ensure that the state is treating its citizens fairly. The governor’s speech came a few months after he signed two executive orders that regulated the sale of delta-8 THC products and permitted patients to possess not more than eight ounces of medical marijuana purchased from other states, provided certain criteria was met.

The use of marijuana for therapeutic purposes isn’t a random thing; plenty of studies have documented its medicinal potential. This is why for-profit companies such as India Globalization Capital Inc. (NYSE American: IGC) are also conducting preclinical and clinical development programs with the objective of bringing to market formulations for conditions such as chronic pain.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Cannabis Legalization Bill in Minnesota Sees Major Overhaul

Earlier this year, a Minnesota House committee approved a measure to legalize recreational cannabis for adults in the state. The legislation was an updated version of a recreational cannabis bill that had advanced from the Minnesota House but failed to pass the then-Republican-controlled Senate.

Once it was approved, the bill was set to be scrutinized by more than 10 committees in the House before heading to the Senate. The recreational cannabis measure recently got a major overhaul and was amended to include new language to protect Minnesota’s nascent low-potency drinkables and edibles segment. Low-potency cannabis products are made using THC (delta-9 tetrahydrocannabinol) from industrial hemp rather than marijuana.

Although both hemp and marijuana are in the cannabis family of plants, industrial hemp is required by law to contain less than 0.3% THC while state-legal marijuana has no such limits.

Legislators in the state and local government committee added the hemp provisions to the Senate version of the bill. House Commerce Committee chairman and lead House author Representative Zack Stephenson said that similar language will be added to the House version of the bill this week. Colead author, Senator Lindsey Port, told the local and state government panel that cannabis prohibition is a “failed system” that hasn’t achieved any of its goals.

Prohibitionist policies were first launched under the guise of tackling drug addiction and defunding the criminal organizations that run the drug trade, but those policies disproportionately affected communities of color and exacerbated already existing racial paradigms.

Port noted that the 142-page amendment focused on licensing and regulatory provisions to address feedback from stakeholders in the low-THC segment.

Unlike cannabis businesses, which have very limited access to capital and banking services, players in the hemp industry can access capital and deduct business expenses from their taxes. However, the two expressed concern that the measure’s original language would lump some entities too closely with incoming marijuana businesses and limit access to crucial financial services. Port also said that the amendments gave local governments more control over cannabis markets but prevented government officials from issuing total bans on marijuana businesses within their jurisdictions.

Both Senate and House versions of the bill have gone through more than 20 committees and are expected to pass through a few more before heading to a vote on the floor.

The House version will likely pass the floor vote as the House already passed a previous version of the bill last year, but the bill’s chances in the Senate will depend on whether its backers can secure enough votes. Stephenson said that he believes the bill has strong support and that they may have even secured support from some Republican lawmakers by the time the measure gets to the floor.

As these legislators move to bring an end to marijuana prohibition in the state, entities elsewhere such as India Globalization Capital Inc. (NYSE American: IGC) are making promising strides in their bids to develop medicinal formulations from cannabis that will pass FDA scrutiny and be approved for use against conditions such as chronic pain.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Synthetic Cannabinoids Drive Wedge Between Hemp, Marijuana Industries

Gold Spectrum, a hemp company based in Tennessee, is the most recent company to introduce a new line of edibles called Delta 8+ THC-O Cereal Bars, widening the rift between the hemp and marijuana industries. Since the 2018 farm bill’s passage, delta-8 THC has gained widespread acceptance as a marijuana substitute in states where it is illegal, including Tennessee.

THC-O is a relatively recent discovery; it is a synthetic cannabinoid produced through chemical synthesis that packs an intoxicating punch. It is also not covered by the farm bill such as naturally occurring cannabinoids derived from hemp.

However, a growing number of states, including Utah, Connecticut and Virginia, have taken action to ban intoxicating cannabinoids derived from hemp, such as THC-O and other THC isomers, including delta-10 and delta-6 THC.

The standoff draws attention to the numerous new cannabinoids that have been released onto the market and the difficulties in regulating access to them. Additionally, it emphasizes the gulf and escalating hostility between licensed marijuana businesses and the widely unregulated hemp industry, where businesses are peddling intoxicating goods containing an expanding variety of synthetic cannabinoids derived from hemp.

On one end, manufacturers and sellers of cannabinoids derived from hemp contend that the farm bill protects their goods and entitles them to unrestricted sale in states with no such laws. On the other hand, the scientific community, consumer watchdogs and regulated marijuana businesses are raising concerns about the safety of synthetic cannabinoids and the confusion they are causing in the market.

Federal authorities have mostly shied away from the matter. In January, the Food and Drug Administration announced that it would not regulate CBD-containing products, deferring instead to Congress, where partisan gridlock has prevented cannabis reform from moving forward to date.

Brightfield Group, a Chicago-based marijuana analytics company, predicts that sales of cannabinoid products will surpass $2.3 billion in 2023 and could double by 2027. However, the forecast failed to account for current state policy limitations or the uncertainty surrounding the potential scope of the proposed changes to the farm bill.

Some policy experts and industry insiders believe that the extensive legislation — renewal of the 2018 farm bill — may help to clear the air regarding new cannabinoids, concentration levels and restrictions. It’s interesting to note that over the past few years, fewer people are buying CBD goods online, while sales at vape and smoke shops have significantly increased, possibly as a result of the increased number of CBD stores in small towns, big cities and everywhere in between.

According to Brightfield, 17.5% of consumers bought CBD goods online in the last quarter of 2022, a decrease from 50.6% during the corresponding period in 2020. In contrast, 33.4% of consumers made purchases at smoke and vape shops in that same period, an increase from 19.1% in 2020.

Away from the feud between recreational marijuana and the hemp industry, there is a growing number of companies such as India Globalization Capital Inc. (NYSE American: IGC) that are working to see cannabis-based formulations approved by the FDA and other regulatory agencies overseeing the health sector in different countries.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

India Globalization Capital Inc. (NYSE American: IGC) Reports Triple-Digit Revenue Growth, Phase 2 Study Highlights in Q3 2023 Report

Net revenue increased 133% to $332,000 in the three months ended Dec. 31, 2022, the company reports
Corporate highlights included expanded trial sites, enrollment for phase 2 IGC-AD1 study
Commencement of study marks milestone in IGC’s progress toward gaining FDA approval for proprietary treatment

In a fragile economic environment, the third-quarter 2023 financial results reported by India Globalization Capital (NYSE American: IGC) are particularly remarkable. The company, which is pursuing effective treatment for Alzheimer’s patients suffering with agitation and other neuropsychiatric symptoms, released a report showing an increase in net revenue of 133% for the three-month period ending Dec. 31, 2023, and an increase in net revenue of 175% for the nine-month period ending the same day (https://ccw.fm/a2EnL).

“Net revenue increased 133% to $332,000 in the three months ended Dec. 31, 2022, compared to $142,000 in the three months ended Dec. 31, 2021,” the company reported. “Net revenue increased 172% to $745,000 for the nine months ended Dec. 31, 2022, compared to $275,000 for the nine months ended Dec. 31, 2021, driven mainly by the company’s life-science segment, which includes, among others, natural products targeting women with premenstrual syndrome (‘PMS’), period pain and sleep disorder.”

The report also noted corporate highlights for the quarter, two of which are related to the company’s phase 2 clinical trial evaluating IGC-AD1 for agitation in dementia from Alzheimer’s disease. The report stated that the number of sites participating in the trial has expanded to a total of four — three in the United States and one in Canada — and that the trial will enroll 146 patients, with one-half of the participants receiving a placebo and the other half receiving IGC-AD1.

“The company is encouraged by the patient enrollment and interest from many of the leading research centers and has decided to increase the number of trial sites to between 10 and 12 from the originally planned four to five,” the company observed. “This will help accelerate the timeline for completion and diversify the patient demographics.” The goal of the trial, the company went on to explain, is to evaluate and establish over a six-week period the efficacy of IGC-AD1 in treating agitation in dementia from Alzheimer’s disease.

“We are delighted with the progress made during this quarter, highlighted by the commencement of the phase 2 clinical trial for our drug candidate IGC-AD1 for the safety and efficacy of the drug on agitation in dementia due to Alzheimer’s disease,” said IGC CEO Ram Mukunda. “This represents a milestone in our progress towards gaining FDA approval for IGC-AD1, which we believe has the potential to revolutionize the treatment of Alzheimer’s disease as the first and only low-dose, natural, THC-based candidate currently undergoing FDA trials.

Moreover, our sales of natural products, which include gummies and pain relief creams, are seeing increased traction in the market,” he continued. “We’re encouraged by our third quarter results and look forward to driving continued expansion through the balance of fiscal 2023.”

IGC develops advanced cannabinoid-based formulations for treating diseases, including but not limited to Alzheimer’s disease, Parkinson’s disease, chronic pain and pet seizures. The company sells various brands of CBD-based consumer products, including Holief, which includes gummies and pain relief creams for women experiencing premenstrual syndrome and dysmenorrhea (period cramps). The company operates facilities in the United States under Good Manufacturing Practices.

For more information, visit the company’s website at www.IGCPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://cnw.fm/IGC

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Florida House Committee Approves Bill Allowing Telehealth Medical Cannabis Certification

A Florida House Committee has unanimously approved a measure that would allow the use of telehealth in certain aspects of cannabis treatment. Bill HB 387 would make it possible for doctors to use telehealth to renew their patients’ medical cannabis approvals. According to sponsor Rep Spencer Roach, the bill would treat medical cannabis like any other pharmaceutical.

Venice-based physician Dr. Barry Gordon told the House Health Care Regulation Subcommittee before the vote that leveraging telehealth to renew medical cannabis certifications would benefit the most vulnerable Floridians.

As dozens of states have legalized marijuana for medical use, millions of people across the country have signed up for medical cannabis access. A large portion of these medical cannabis patients (32.5%) are aged 50 to 64 years of age, and medical cannabis use among older people has been steadily increasing as the drug loses its stigma.

Cannabis is also effective against conditions that tend to affect older people, including chronic pain from arthritis, insomnia, mood disorders and cancer-related symptoms. In the wake of the coronavirus pandemic, several states across the United States approved cannabis home delivery to protect vulnerable and immunocompromised patients and limit their exposure to infection.

Gordon, who specializes in medical cannabis treatment, noted that medical marijuana patients tend to be the weakest and most debilitated in Florida. The new bill is meant to protect such patients from potential exposure to diseases on top of reducing treatment costs for patients.

Florida law currently requires that doctors must be “physically present in the same room as the patient” to conduct a physical examination and provide a medical cannabis prescription. Although Governor Ron DeSantis suspended this requirement temporarily during the pandemic, it was only available for patients who were renewing their certifications at a physician they had seen before.

Some physicians have continued to use telehealth in medical cannabis treatment even though the governor’s order expired in mid-2021.

If the measure is signed into law, it will give the Department of Health the power to ban physicians from providing and renewing medical cannabis certifications for up to two years if they “provide, advertise or market” medical cannabis telehealth services before July 1, 2023.

Roach noted that the Department of Health is currently required to pass complaints regarding medical marijuana physicians to its Division of Medical Quality Assurance, which can be quite a long process. His measure would provide the state agency with a “necessary and immediate tool” to help it deal with doctors who break medical cannabis rules.

As the users of medical marijuana increase by the day, another noteworthy trend is the increasing amount of R&D work being undertaken by for-profit entities such as India Globalization Capital Inc. (NYSE American: IGC) in a bid to commercialize pharmaceutical-grade. cannabis-based formulations that meet the strict requirements of the FDA.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Congressional Lawmakers Want Cannabis Scheduling Review More Transparent

On March 9, 2023, a group of nonpartisan Congress legislators penned a letter to senior Biden administration figures asking for transparency on the president’s ongoing review of marijuana’s legalization. A draft of the letter was recently distributed by Rep. Earl Blumenauer (D-OR) among Congress for signatures before being sent to Xavier Becerra, secretary of Health and Human Services (HHS), and Merrick Garland, United States attorney general.

According to the letter’s content, Biden’s scheduling directive presents a chance to evaluate the causes and effects of federal law in an open-minded manner. It also states that cannabis scheduling was based on prejudice rather than science and that it is time to face the fact that cannabis is currently a state-regulated drug.

The legislators stated that administrative descheduling would not absolve Congress of its duty to enact comprehensive federal marijuana reform owing to the fact that there have been numerous well-considered reform proposals presented in previous sessions. All of these bills and proposals, according to the letter, aim to honor the state-led initiative that has been going on for 50 years to reexamine marijuana policy in the context of the failed and prejudiced war on drugs.

There are 16 signatories to the letter, including Representatives Lou Correa, Barbara Lee, Nancy Mace, Mark Pocan, Dina Titus, Bonnie Coleman, Eleanor Holmes Norton, Val Hoyle, Donald Payne, Sydney Kamlager-Dove, Jim McGovern, Nikema Williams, Jan Schakowsky and Jared Huffman, as well as Blumenauer, cochair of the Congress Marijuana Caucus.

In the meantime, Becerra responded to another letter addressed to President Joseph Biden in December about the need for the government to acknowledge the benefits of cannabis descheduling and adopt a firm stance. The response letter was sent to lawmakers, including Lee and Blumenauer.

Instead of responding to the lawmakers’ main request, the HHS office merely reaffirmed the department’s responsibility for conducting the marijuana review and concluded by stating that the Drug Enforcement Administration (DEA) makes the ultimate decision following the completion of a comprehensive scientific analysis.

In a separate statement, the attorney general said that the Department of Justice is still drafting a cannabis policy while awaiting the scientific review’s findings from different health agencies.

On the other hand, Biden has often touted his marijuana scheduling order and pardons in the past few months, with his most recent proclamation made at a celebration marking the conclusion of African American History Month.

The outcome of the ongoing scheduling review could have widespread impacts on various companies, such as India Globalization Capital Inc. (NYSE American: IGC), that are seeking to develop medicines from cannabis compounds such as THC.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.